|
Start Date:3/22/2022
Start Time:10:00 AM EDT
Duration:120 minutes
Abstract:
Otonomy, Inc. (NASDAQ: OTIC) is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. Please join us for our 2022 Virtual Investor R&D Event to learn how Otonomy is working to transform the treatment of tinnitus and hearing loss, with multiple upcoming clinical trial readouts. This event will include presentations by key opinion leaders who will provide background information on tinnitus and hearing loss and review the positive Phase 1/2 trial results for both OTO-313 and OTO-413. Additionally, Otonomy’s senior management team will provide an update on ongoing clinical trials and outline next steps for these programs.
If you're already registered for the Otonomy Investor R&D Event 2022 webcast, click below:
ALREADY REGISTERED?
Speakers
Barbara Shinn-Cunningham, Ph.D. Director, Carnegie Mellon Neuroscience Institute and Cowan Professor of Auditory Neuroscience, Biomedical Engineering, Psychology, and Electrical & Computer Engineering at Carnegie Mellon University
Victoria Sanchez, Au.D., Ph.D. Assistant Professor in Department of Otolaryngology - Head & Neck Surgery at University of South Florida
Anthony Mikulec, M.D. Professor of Otologic, Neurotologic and Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, Saint Louis University
Mr. John Phillips, PhD MBBS MRCS (Eng) FRCS (ORL-HNS), Consultant ENT Surgeon
Norfolk & Norwich University Hospitals NHS Foundation Trust, United Kingdom
David. A. Weber, Ph.D. President & Chief Executive Officer, Otonomy
Alan C. Foster, Ph.D. Chief Scientific Officer, Otonomy
Jeffrey J. Anderson, Ph.D. Vice President, Clinical Sciences, Otonomy
Paul E. Cayer Chief Financial & Business Officer, Otonomy
|
Otonomy Investor R&D Event 2022
Registration Is Closed
|
|
|
|